下一代测序技术在先天性溶血性贫血中的应用:系统性审查和元分析
1Blood Transfusion Department, The Seventh Affiliated Hospital, Sun Yat-Sen University, No. 628, Zhenyuan Road, Xinhu Street, Guangming District, Shenzhen City, 518107, Guangdong Province, China.
Clinical and experimental medicine
|November 11, 2025
概括
下一代测序 (NGS) 有效地诊断出先天性血液溶解性贫血 (CHA),在近一半的患者中确定遗传原因. 这种先进的基因测试在家族病例和特定贫血亚型中显示出更高的成功率,支持其在临床实践中的使用.
科学领域:
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
- 医学诊断 医学诊断 医学诊断
背景情况:
- 由于其遗传复杂性,先天性血液溶解性贫血 (CHA) 存在重大诊断挑战.
- 目前的诊断方法往往难以确定CHA的潜在遗传原因.
研究的目的:
- 系统地审查和元分析下一代测序 (NGS) 对先天性血液溶解性贫血 (CHA) 的诊断疗效.
- 评估NGS在不同CHA亚型和患者人口统计学方面的表现.
主要方法:
- 在PubMed和Web of Science数据库中进行系统的文献搜索,直到2025年4月.
- 包括在CHA患者中使用NGS技术 (WES,WGS,CES,向面板) 的研究.
- 随机效应元分析以计算聚合的阳性检测率和置信区间,并进行子组分析.
主要成果:
- 在CHA中,NGS的综合阳性检测率为44.3% (95%CI:32.4-56.3%).
- 与零星病例 (16.9%) 相比,具有家族病史的患者 (51.0%) 的检测率显著更高.
- 红细胞膜疾病显示出最高的诊断产量 (45.3%),其中SPTB,ANK1和SPTA1是关键基因.
结论:
- NGS为CHA提供了大量的诊断实用性,解决了近一半的病例和超过50%的家族表现.
- 这些发现支持将NGS整合到一线CHA诊断中,特别是针对性基因面板以实现成本效益.
- 经常发现特定的基因突变 (SPTB,PKLR,ANK1,SLC4A1,SPTA1),有助于诊断和了解疾病机制.
相关概念视频
Next-generation Sequencing
97.5K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
97.5K
Genome-wide Association Studies-GWAS
15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.2K


